E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10011078 |
E.1.2 | Term | Coronary artery disease |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To evaluate the effects on the coronary vasculature, as assessed by myocardial perfusion/coronary flow reserve, at the end of treatment (EoT) of 48 hours i.v. administration of 30 μg/kg/24h serelaxin or placebo in patients with coronary artery disease
• To evaluate the effects on augmentation index (AIx) at the end of treatment (EoT) of 48 hours i.v. administration of 30 μg/kg/24h serelaxin or placebo in patients with coronary artery disease |
|
E.2.2 | Secondary objectives of the trial |
• To evaluate the effects on aortic distensibility by MRI and pulse wave velocity (PWV) by Sphygmocor , at the end of treatment (EoT) of 48 hours i.v. administration of 30 μg/kg/24h serelaxin or placebo in patients with coronary artery disease
• To evaluate the effects on augmentation index (AIx) and pulse wave velocity (PWV) by Sphygmocor at the end of treatment (EoT) of 48 hours i.v. administration of 30μg/kg/24h serelaxin or placebo and at Day 30 and Day 180
• To assess the safety and tolerability of 48 hours i.v. infusion of serelaxin in patients with coronary artery disease
• To assess the pharmacokinetics of 48 hours i.v. administration of 30 μg/kg/24h serelaxin infusion in patients with coronary artery disease |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Male and female patients ≥18 years of age, with body weight <160 kg.
• Patients with proven obstructive coronary artery disease, determined either by functional (e.g. treadmill testing) or non-invasive clinical imaging assessments (e.g. stress-echo, PET or SPECT myocardial perfusion), or invasive coronary angiography or by CT coronary angiography at any point in time in patients with or without mild left ventricular systolic
dysfunction (LVSD). |
|
E.4 | Principal exclusion criteria |
• Previous treatment with serelaxin (also known as: RLX030, relaxin)
• Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing of study treatment.
• Current or planned dialysis.
• Impaired renal function during screening defined as an estimated glomerular filtration rate (eGFR) at screening and prior to treatment of <30 mL/min/1.73 m2, calculated using the simplified Modification of Diet in Renal Disease (sMDRD) equation due to potential issue with administration of GdDTPA used as the MRI contrast agent.
• Sick-Sinus-Syndrome
• Current or history of pulmonary edema, including suspected sepsis.
• Known significant valvular disease (including any of the following: severe aortic stenosis [AVA < 1.0 or peak gradient > 50 on prior or current echocardiogram], severe aortic regurgitation, or severe mitral stenosis).
• Clinical diagnosis of acute coronary syndrome (ACS) including unstable angina within 30 days prior to screening as determined by both clinical and enzymatic criteria
• Troponin elevation and dynamics indicative of ACS at any time between screening and randomization.
• Previous myocardial infarction within 3 months of screening
• History of Coronary Artery Bypass Graft (CABG) surgery
• Heart failure due to significant arrhythmias (including any of the following:
ventricular tachycardia, bradyarrhythmias with ventricular rate < 45 beats per minute or any second or third degree AV block or atrial fibrillation/flutter with ventricular response of > 120 beats per minute)
• Any surgical or medical condition which in the opinion of the investigator may place the patient at higher risk from his/her participation in the study (e.g., history of poor tolerance of adenosine or 3 vessel coronary disease)
• Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy (does not include restrictive mitral filling patterns seen on Doppler echocardiographic assessments of diastolic function). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Change from baseline in microvascular function assessed by regional and global determinations of myocardial perfusion
- Change from baseline in macrovascular function assessed by augmentation index (AIx) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
respectively at:
-At pre-dose on Day 1 (baseline) and prior to the end of the 48 hour drug infusion
-From pre-dose on Day 1 (baseline) until prior to the end of the 48h drug infusion |
|
E.5.2 | Secondary end point(s) |
1. Change from baseline in aortic distensibility
2. Change from baseline in augmentation index
3. Change from baseline in pulse wave velocity
4. Number of participants with adverse events, serious adverse events, and death
5. Serum concentration of serelaxin
6. Serum concentration of ntibodies to serelaxin
7. Systemic clearance of serelaxin |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. 2. 3. At pre-dose on day 1 (baseline) until Day 180 after the start of drug infusion
4. From the screening visit until Day 180
5. 6. From pre-dose on Day 1 until Day 30 after the start of drug infusion
7. From pre-dose on Day 1 until 48h after the start of drug infusion. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |